Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.
OBJECTIVE
Androgen replacement has been reported to increase bone mineral density (BMD) in hypogonadal men. We studied the effects of 6 months of treatment with a new transdermal testosterone (T) gel preparation on bone turnover markers and BMD.


METHODS
This was a prospective, randomized, multicentre, parallel clinical trial where 227 hypogonadal men, mean age 51 years (range: 19-68 years) were studied in 16 academic and research institutions in the USA. Subjects were randomized to apply 1% T gel containing 50 or 100 mg T (delivering approximately 5-10 mg T/day) or two T patches (delivering 5 mg T/day) transdermally for 90 days. At day 91, depending on the serum T concentration, the T gel dose was adjusted upward or downward to 75 mg T/day until day 180. No dose adjustment occurred in the T patch group.


METHODS
Serum T, free T and oestradiol, bone turnover markers and BMD were measured on days 0, 30, 90 and 180 before and after treatment.


RESULTS
Application of T gel 100 mg/day resulted in serum T concentrations 1.4 and 1.9-fold higher than in the T gel 50 mg/day and the T patch groups, respectively. Proportional increases occurred in serum oestradiol. Urine N-telopeptide/creatinine ratio, a marker for bone resorption, decreased significantly (P = 0.0019) only in the T gel 100 mg/day group. Serum bone osteoblastic activity markers (osteocalcin, procollagen and skeletal alkaline phosphatase) increased significantly during the first 90 days of treatment without intergroup differences but declined to baseline thereafter. BMD increased significantly both in the hip (+1.1 +/- 0.3%) and spine (+2.2 +/- 0.5%) only in the T gel 100 mg/day group (P = 0.0001).


CONCLUSIONS
Transdermal testosterone gel application for 6 months decreased bone resorption markers and increased osteoblastic activity markers for a short period, which resulted in a small but significant increase in BMD. Ongoing long-term studies should answer whether the observed increases in BMD are sustained or continue to be dependent on the dose of testosterone administered.
Wang
C
C
Divisions of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Research and Education Institute, Torrance, CA, USA. wang@gcrc.humc.edu
Swerdloff
R S
RS
Iranmanesh
A
A
Dobs
A
A
Snyder
P J
PJ
Cunningham
G
G
Matsumoto
A M
AM
Weber
T
T
Berman
N
N
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects*; D002118:Calcium / Q000097:blood; D003094:Collagen / Q000652:urine; D024042:Collagen Type I; D003404:Creatinine / Q000652:urine; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D005782:Gels; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010455:Peptides / Q000652:urine; D010758:Phosphorus / Q000097:blood; D011347:Procollagen / Q000097:blood; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood / Q000627:therapeutic use*
D015415:Biomarkers; D024042:Collagen Type I; D005782:Gels; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D010758:Phosphorus; D013739:Testosterone; D004958:Estradiol; D003094:Collagen; D003404:Creatinine; D000469:Alkaline Phosphatase; D002118:Calcium